On the population pharmacokinetics and the enterohepatic recirculation of total ezetimibe

References

• Abi Khalil F, Hanocq M, Dubois J. (1993). A new method to estimate parameters of pharmacokinetics with enterohepatic circulation. Eur J Drug Metab Pharmacokinet 18:131–9.
   PubMed Web of Science ®Google Scholar
• Ballantyne CM, Houri J, Notarbartolo A, et al. (2003). Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circulation 107:2409–15.
   PubMed Web of Science ®Google Scholar
• Bays HE, Moore PB, Drehobl MA, et al. (2001). Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia: pooled analysis of two phase II studies. Clin Ther 23:1209–30.
   PubMed Web of Science ®Google Scholar
• Berg AK, Mandrekar SJ, Ziegler KL, et al. (2013). Population pharmacokinetic model for cancer chemoprevention with sulindac in healthy subjects. J Clin Pharmacol 53:403–12.
   PubMed Web of Science ®Google Scholar
• Chu NN, Chen WL, Xu HR, Li XN. (2012). Pharmacokinetics and safety of ezetimibe/simvastatin combination tablet: an open-label, single-dose study in healthy Chinese subjects. Clin Drug Investig 32:791–8.
   PubMed Web of Science ®Google Scholar
• Colburn WA. (1982). Pharmacokinetic and biopharmaceutic parameters during enterohepatic circulation of drugs. J Pharm Sci 71:131–3.
   PubMed Web of Science ®Google Scholar
• Colom H, Lloberas N, Andreu F, et al. (2014). Pharmacokinetic modeling of enterohepatic circulation of mycophenolic acid in renal transplant recipients. Kidney Int 85:1434–43.
   PubMed Web of Science ®Google Scholar
• de Waart DR, Vlaming ML, Kunne C, et al. (2009). Complex pharmacokinetic behavior of ezetimibe depends on abcc2, abcc3, and abcg2. Drug Metab Dispos 37:1698–702.
   PubMed Web of Science ®Google Scholar
• de Winter BC, van Gelder T, Sombogaard F, et al. (2009). Pharmacokinetic role of protein binding of mycophenolic acid and its glucuronide metabolite in renal transplant recipients. J Pharmacokinet Pharmacodyn 36:541–64.
   PubMed Web of Science ®Google Scholar
• Dujovne CA, Ettinger MP, McNeer JF, et al. (2002). Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia. Am J Cardiol 90:1092–7.
   PubMed Web of Science ®Google Scholar
• Ezzet F, Krishna G, Wexler DB, et al. (2001). A population pharmacokinetic model that describes multiple peaks due to enterohepatic recirculation of ezetimibe. Clin Ther 23:871–85.
   PubMed Web of Science ®Google Scholar
• Gao Y, Shao J, Jiang Z, et al. (2014). Drug enterohepatic circulation and disposition: constituents of systems pharmacokinetics. Drug Discov Today 19:326–40.
   PubMed Web of Science ®Google Scholar
• Jain L, Woo S, Gardner ER, et al. (2011). Population pharmacokinetic analysis of sorafenib in patients with solid tumours. Br J Clin Pharmacol 72:294–305.
   PubMed Web of Science ®Google Scholar
• Jeu L, Cheng JW. (2003). Pharmacology and therapeutics of ezetimibe (SCH 58235), a cholesterol-absorption inhibitor. Clin Ther 25:2352–87.
   PubMed Web of Science ®Google Scholar
• Jiao Z, Shen J, Ding JJ, et al. (2007). Modified population pharmacokinetic model for enterohepatic circulation of mycophenolic acid and its application in a bioequivalence study. Asian J Pharmacodyn Pharmacokinet 7:153–60.
   Google Scholar
• Kim TH, Shin S, Landersdorfer CB, et al. (2015). Population pharmacokinetic modeling of the enterohepatic recirculation of fimasartan in rats, dogs, and humans. AAPS J 17:1210–23.
   PubMed Web of Science ®Google Scholar
• Kosoglou T, Statkevich P, Johnson-Levonas AO, et al. (2005). Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. Clin Pharmacokinet 44:467–94.
   PubMed Web of Science ®Google Scholar
• Malik MY, Jaiswal S, Sharma A, et al. (2016). Role of enterohepatic recirculation in drug disposition: cooperation and complications. Drug Metab Rev 48:281–327.
   PubMed Web of Science ®Google Scholar
• Nashimoto S, Sato Y, Takekuma Y, Sugawara M. (2017). Inhibitory effect of ezetimibe can be prevented by an administration interval of 4 h between α-tocopherol and ezetimibe. Biopharm Drug Dispos 38:280–9.
   PubMed Web of Science ®Google Scholar
• Okour M, Brundage RC. (2017). Modeling enterohepatic circulation. Curr Pharmacol Rep 3:301–13.
   Google Scholar
• Patel J, Sheehan V, Gurk-Turner C. (2003). Ezetimibe (Zetia): a new type of lipid-lowering agent. Proc (Bayl Univ Med Cent) 16:354–8.
   PubMedGoogle Scholar
• Patrick JE, Kosoglou T, Stauber KL, et al. (2002). Disposition of the selective cholesterol absorption inhibitor ezetimibe in healthy male subjects. Drug Metab Dispos 30:430–7.
   PubMed Web of Science ®Google Scholar
• Roberts MS, Magnusson BM, Burczynski FJ, Weiss M. (2002). Enterohepatic circulation: physiological, pharmacokinetic and clinical implications. Clin Pharmacokinet 41:751–90.
   PubMed Web of Science ®Google Scholar
• Sam WJ, Akhlaghi F, Rosenbaum SE. (2009). Population pharmacokinetics of mycophenolic acid and its 2 glucuronidated metabolites in kidney transplant recipients. J Clin Pharmacol 49:185–95.
   PubMed Web of Science ®Google Scholar
• Sam WJ, Joy MS. (2010). Population pharmacokinetics of mycophenolic acid and metabolites in patients with glomerulonephritis. Ther Drug Monit 32:594–605.
   PubMed Web of Science ®Google Scholar
• Shou M, Lu W, Kari PH, et al. (2005). Population pharmacokinetic modeling for enterohepatic recirculation in Rhesus monkey. Eur J Pharm Sci 26:151–61.
   PubMed Web of Science ®Google Scholar
• Smith DA, Beaumont K, Maurer TS, Di L. (2015). Volume of distribution in drug design. J Med Chem 58:5691–8.
   PubMed Web of Science ®Google Scholar
• Soulele K, Macheras P, Karalis V. (2017). Pharmacokinetic analysis of inhaled salmeterol in asthma patients: evidence from two dry powder inhalers. Biopharm Drug Dispos 38:407–19.
   PubMed Web of Science ®Google Scholar
• Soulele K, Macheras P, Silvestro L, et al. (2015). Population pharmacokinetics of fluticasone propionate/salmeterol using two different dry powder inhalers. Eur J Pharm Sci 80:33–42.
   PubMed Web of Science ®Google Scholar
• Strandgården K, Höglund P, Grönquist L, et al. (2000). Absorption and disposition including enterohepatic circulation of (14C) roquinimex after oral administration to healthy volunteers. Biopharm Drug Dispos 21:53–67.
   PubMed Web of Science ®Google Scholar
• Sudhop T, Lütjohann D, Kodal A, et al. (2002). Inhibition of intestinal cholesterol absorption by ezetimibe in humans. Circulation 106:1943–8.
   PubMed Web of Science ®Google Scholar
• Sweeney ME, Johnson RR. (2007). Ezetimibe: an update on the mechanism of action, pharmacokinetics and recent clinical trials. Expert Opin Drug Metab Toxicol 3:441–50.
   PubMed Web of Science ®Google Scholar
• van Heek M, Farley C, Compton DS, et al. (2000). Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH58235, and its glucuronide, SCH60663. Br J Pharmacol 129:1748–54.
   PubMed Web of Science ®Google Scholar
• van Heek M, France CF, Compton DS, et al. (1997). In vivo metabolism-based discovery of a potent cholesterol absorption inhibitor, SCH58235, in the rat and rhesus monkey through the identification of the active metabolites of SCH48461. J Pharmacol Exp Ther 283:157–63.
   PubMed Web of Science ®Google Scholar
• Wajima T, Yano Y, Oguma T. (2002). A pharmacokinetic model for analysis of drug disposition profiles undergoing enterohepatic circulation. J Pharm Pharmacol 54:929–34.
   PubMed Web of Science ®Google Scholar
• Yau WP, Vathsala A, Lou HX, et al. (2009). Mechanism-based enterohepatic circulation model of mycophenolic acid and its glucuronide metabolite: assessment of impact of cyclosporine dose in Asian renal transplant patients. J Clin Pharmacol 49:684–99.
   PubMed Web of Science ®Google Scholar
• Younis IR, Malone S, Friedman HS, et al. (2009). Enterohepatic recirculation model of irinotecan (CPT-11) and metabolite pharmacokinetics in patients with glioma. Cancer Chemother Pharmacol 63:517–24.
   PubMed Web of Science ®Google Scholar